Immune Thrombotic Thrombocytopenic Purpura Following Trimethoprim Sulfamethoxazole Reexposure: A Case Report Authors: Renee Morecroft, Jyoti Moorjani, Mohamed Hussam Hallak, Tathana Rivera Hernandez, Isabella Estrada, Hammad Awad, Payam Nabizadeh‐Eraghi Published: 2026 ABSTRACT ABSTRACTAn 85‐year‐old man developed acute neurologic dysfunction, severe thrombocytopenia, microangiopathic hemolytic anemia, and ADAMTS13 activity of 4.6% after TMP‐SMX reexposure. Seven plasma‐exchange sessions plus corticosteroids produced rapid recovery. This case highlights the diagnostic challenge of possible TMP‐SMX–associated iTTP and the importance of prompt treatment.Keywords: case report, immune‐mediated thrombotic thrombocytopenic purpura, plasma exchange, trimethoprim–sulfamethoxazole Introduction Any causal relationship between trimethoprim‐sulfamethoxazole (TMP‐SMX) and thrombotic thrombocytopenic purpura (TTP) would be exceptionally uncommon, given that the annual incidence of immune‐mediated TTP (iTTP) is estimated at only two to six cases per million individuals [1]. Of this, drug‐associated TTP accounts for approximately 5% of all cases, as suggested by national registry data. This corresponds to an incidence of fewer than 0.2 cases per million [1]. This exceedingly low frequency stands in stark contrast to the widespread use of prescription medications, rendering drug‐induced TTP an exceptionally rare and diagnostically elusive entity. TMP‐SMX has been rarely associated with TTP, with only a limited number of cases reported in the literature [2, 3, 4]. TMP‐SMX was prescribed to over 3 million people in 2023, further highlighting the uniqueness of this case [5]. Proposed mechanisms include drug‐dependent antibodies that inhibit or accelerate clearance of ADAMTS13, immune‐mediated endothelial injury leading to microangiopathy, or hypersensitivity‐related vascular inflammation that precipitates thrombosis [2, 3, 4]. TMP‐SMX‐associated TTP poses a diagnostic challenge due to its rarity, nonspecific presenting features, and frequent confounding by infection or sepsis—conditions that themselves may cause thrombocytopenia and hemolysis. Delayed recognition may lead to rapid clinical deterioration, particularly in older adults with multiple comorbidities. Early identification of drug exposure and initiation of plasma exchange (PLEX) are therefore critical. Here, we present a case of TMP‐SMX‐associated TTP in an elderly patient. This case highlights the importance of maintaining a high index of suspicion for drug‐induced TTP, even with commonly prescribed antibiotics, and underscores the life‐saving impact of early PLEX and immunosuppressive therapy. Case History/Examination An 85‐year‐old man with a medical history notable for dementia, coronary artery disease status post coronary artery bypass grafting, and bilateral subdural hematomas following a mechanical fall (status post craniotomy 4 months prior, complicated by secondary infection with Bacteroides fragilis and Corynebacterium species) presented with acute altered mental status and abnormal laboratory findings identified during a primary care visit. His history was further notable for recurrent lower urinary tract infections, including a recent unresolved infection initially treated with TMP‐SMX 160/800 mg twice a day for 7 days, subsequently switched to clindamycin, and then restarted on the same dose and duration of TMP‐SMX due to persistent symptoms. Of note, he has no allergies. On admission, 3 days after restarting TMP‐SMX, the patient met the criteria for severe sepsis. Physical examination revealed a frail, chronically ill‐appearing elderly man who was lethargic. Neurologic examination demonstrated altered mental status, dysarthric speech, and nuchal rigidity without focal motor or sensory deficits. No petechiae or ecchymoses were observed. Notably, baseline labs from four months prior showed hemoglobin 8.1 g/dL, platelet count of 383 × 109/L, prothrombin time (PT) of 12.4, partial thromboplastin time (PTT) of 37, and international normalized ratio (INR) of 1.08 (Table 1). TABLE 1Laboratory values at presentation and during plasma exchange therapy.Laboratory parameter4 months before admissionAdmission before PLEXAfter PLEX 1After PLEX 3Latest available during treatmentPlatelet count (×109/L)38381022170 after PLEX 7Hemoglobin (g/dL)8.15.810.210.812.6 after PLEX 7INR1.081.321.24NRNRFibrinogen (mg/dL)NR182175200208 after PLEX 4Creatinine (mg/dL)0.801.721.081.060.97 after PLEX 7LDH (U/L)NR20252430893327 after PLEX 4ADAMTS13 activity (%)NR4.64.635.360.4 after PLEX 5Abbreviations: INR, international normalized ratio; LDH, lactate dehydrogenase; NR, not reported; PLEX, plasma exchange. Laboratory values at presentation and during plasma exchange therapy. Abbreviations: INR, international normalized ratio; LDH, lactate dehydrogenase; NR, not reported; PLEX, plasma exchange. Differential Diagnosis, Investigations and Treatment Initial laboratory evaluation was concerning for microangiopathic hemolytic anemia (MAHA). Hematologic studies demonstrated severe thrombocytopenia (platelet count 8 × 109/L), profound anemia (hemoglobin 5.8 g/dL) with a hypoproliferative reticulocyte index, mild hypofibrinogenemia (fibrinogen 182 mg/dL), and a prolonged PT of 16.0 s with a normal PTT and mildly elevated INR of 1.32 (Table 1). Peripheral blood smear revealed marked schistocytosis with near absence of platelets (Figure 1). Additional laboratory findings included acute kidney injury (creatinine 1.72 mg/dL from a previously normal baseline), indirect hyperbilirubinemia, lactic acidosis (lactate 6.2 mmol/L), markedly elevated lactate dehydrogenase (LDH 2025 U/L), and elevated cardiac troponin (456.66 ng/L) (Table 1). Peripheral smear demonstrating marked schistocytosis (red arrows) and no platelets. The nine other fields reviewed showed similar morphology. Platelet count on complete blood count = 8 × 109/L. Computed tomography (CT) of the brain without contrast demonstrated chronic bilateral subdural hematomas without evidence of new intracranial hemorrhage (Figure 2A) compared to 4 months prior (Figure 2B). CT of the abdomen and pelvis raised concern for colitis and possible acute cholecystitis (Figure 3); however, subsequent liver ultrasound and hepatobiliary iminodiacetic acid (HIDA) scan were unremarkable. CT Brain on admission (A), showing stable size of bilateral hemispherical subdural fluid collections within the right frontal region (blue arrows) compared to 4 months prior (B). Sagittal view of a CT abdomen and pelvis showing mild scattered wall thickening of the colon (green arrow) concerning colitis. Nonspecific gallbladder distention is present with surrounding inflammation (orange arrow), recommending clinical correlation for possible cholecystitis. The patient was admitted for management of MAHA due to nonovert disseminated intravascular coagulation (DIC) secondary to sepsis versus thrombotic thrombocytopenic purpura (TTP), with an International Society on Thrombosis and Hemostasis (ISTH) DIC score of 4 and a PLASMIC score of 6 (Figure 4), indicating high risk for severe ADAMTS13 deficiency. In the intensive care unit, he underwent close neurologic monitoring and was initiated on broad‐spectrum empiric antimicrobial therapy (intravenous Vancomycin, Cefepime, and Metronidazole) to cover possible meningitis and colitis. Platelet transfusions were given to maintain counts > 50 × 109/L due to high intracranial hemorrhage risk. High‐dose IV methylprednisolone (1 g daily) was started. Lumbar puncture was deferred because of severe thrombocytopenia. ADAMTS13 activity and stool Clostridioides difficile GDH antigen and toxin A/B testing by enzyme immunoassay were obtained, and Hematology/Oncology was consulted to discuss initiation of PLEX. PLASMIC score for TTP calculation for this case. ADAMTS13 activity returned at 4.6%, and LDH increased further to 2430 U/L, confirming severe ADAMTS13 deficiency (Table 1). Given the high bleeding risk associated with central venous catheter placement in the setting of profound thrombocytopenia, the patient initially received fresh frozen plasma (FFP), which resulted in partial improvement in platelet count and hemolysis markers. By hospital day three, the constellation of clinical findings supported a diagnosis of acquired TTP likely associated with TMP‐SMX. Plasma exchange was initiated following stabilization with FFP, resulting in rapid neurologic and laboratory improvement. The stool assay returned positive for Clostridioides difficile. Empiric antimicrobials were discontinued and targeted treatment was initiated with oral vancomycin. The patient underwent a total of seven PLEX sessions with progressive normalization of mental status, platelet recovery, resolution of hemolysis markers, and normalization of ADAMTS13 activity (Figure 5). Corticosteroids were transitioned to oral prednisone at 1 mg/kg/day after 3 days, with a planned taper guided by platelet count, LDH, and ADAMTS13 activity. Graph showing an increase in ADAMTS13 levels and platelet count with a decrease in LDH after each PLEX session. Outcome and Follow‐Up The patient became clinically stable, with return of mental status to baseline and no new focal neurologic deficits, and was subsequently downgraded from the intensive care unit. He was discharged with close outpatient hematology follow‐up. Prednisone taper was recommended only after platelet count ≥ 150 × 109/L, LDH normalization, and ADAMTS13 activity ≥ 20%, with a gradual taper over 2–3 weeks, reducing the dose by 10%–20% every 3–5 days. Weekly monitoring of platelet count, LDH, and ADAMTS13 activity was advised. In the event of relapse or ADAMTS13 activity < 20%, steroid taper would be halted, and therapy escalated. The patient was counseled to strictly avoid future TMP‐SMX exposure due to the risk of rapid and severe recurrence of TTP. This case has been summarized in Figure 6. Chronological summary of key events in this case presentation. Discussion Drug‐associated TTP is an uncommon condition accounting for approximately 5% of all cases and corresponds to fewer than 0.2 cases per million [1]. While several medications, including quinine, ticlopidine, clopidogrel, and certain chemotherapeutic agents, have been strongly linked to TTP, TMP‐SMX has only rarely been implicated [2, 3, 4]. Given the widespread use of TMP‐SMX for common infections, the true incidence of TMP‐SMX–associated TTP is exceedingly low, making recognition challenging and often delayed. This diagnostic difficulty is compounded by the frequent coexistence of infection or sepsis, which may independently cause thrombocytopenia, hemolysis, and multiorgan dysfunction. Several mechanisms have been proposed to explain TMP‐SMX–associated TTP. One hypothesis involves drug‐dependent antibodies that directly inhibit ADAMTS13 activity or accelerate its clearance, resulting in severe functional deficiency and accumulation of ultra‐large vWF (ULvWF) multimers [3, 4]. A second proposed mechanism is immune‐mediated endothelial injury, whereby drug‐induced immune activation leads to endothelial dysfunction and exposure of ULvWF multimers, promoting platelet aggregation and microangiopathy [3]. A third mechanism implicates hypersensitivity‐related vascular inflammation, supported by reports of concurrent drug hypersensitivity features, which may precipitate localized or systemic thrombotic microangiopathy [3]. These mechanisms are not mutually exclusive and may coexist in susceptible individuals, contributing to the heterogeneity of clinical presentations and disease severity. Reported cases of TMP‐SMX–associated TTP demonstrate variable latency but do not establish a dose‐ or duration‐response relationship. Martin et al. described onset within 48 h of starting therapy [4]; Bapani et al. reported symptom onset on Day 7 of treatment for a urinary tract infection [3]; and Herrington et al. described two patients, one with onset shortly after initiation and another on Day 7 [2]. Exact dose and cumulative exposure were incompletely or inconsistently reported across these cases, precluding a formal dose–response or duration‐response assessment. In the present case, TTP occurred within 3 days of TMP‐SMX reexposure, a temporal pattern that is more consistent with an idiosyncratic immune‐mediated reaction than predictable cumulative toxicity [2, 3, 4]. Our case expands the existing literature by describing TMP‐SMX–associated TTP in an elderly patient with multiple comorbidities, initially masquerading as severe sepsis with consumptive coagulopathy. The presence of neurologic dysfunction, cardiac involvement manifested by elevated troponins, severe thrombocytopenia, and microangiopathic hemolytic anemia ultimately supported the diagnosis of TTP. The patient's prompt clinical and laboratory improvement following initiation of PLEX and corticosteroids further reinforces the diagnosis and highlights the life‐saving importance of early intervention. Treatment is based on the 2020 ISTH guidelines, which did not require further update in the 2025 revision [6, 7]. This case emphasizes several important clinical lessons. First, clinicians should maintain a high index of suspicion for TTP in patients with thrombocytopenia and hemolysis, even in the setting of infection or sepsis. Second, a careful review of the medication history, including recent or reinitiated TMP‐SMX exposure, is necessary. Finally, early initiation of PLEX should not be delayed while awaiting confirmatory ADAMTS13 testing when clinical suspicion is high. Avoidance of future TMP‐SMX exposure is essential, as rechallenge may result in rapid and severe recurrence. Whether TMP‐SMX‐associated TTP predicts a similar reaction to other sulfonamide‐containing drugs is unknown. No published evidence establishes cross‐reactive TTP among sulfonamide antibiotics or between antibiotic and nonantibiotic sulfonamides. Moreover, population data do not support clinically meaningful allergic cross‐reactivity between sulfonamide antibiotics and nonantibiotic sulfonamides; however, those allergy data cannot be directly extrapolated to TTP [8]. Accordingly, permanent avoidance of TMP‐SMX is warranted, whereas avoidance of all nonantibiotic sulfonamides solely because of structural similarity is not evidence‐based. Use of another sulfonamide antibiotic should be individualized, with hematology and allergy consultation when clinically necessary. Author Contributions Renee Morecroft: conceptualization, writing – original draft, visualization, writing – review and editing, project administration. Mohamed Hussam Hallak: writing – review and editing. Tathana Rivera Hernandez: writing – review and editing. Hammad Awad: writing – review and editing. Isabella Estrada: writing – review and editing. Payam Nabizadeh‐Eraghi: conceptualization, supervision, writing – review and editing. Jyoti Moorjani: writing – review and editing, writing – original draft, resources. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent Written informed consent was obtained from the patient for publication of this case report and accompanying images. Conflicts of Interest The authors declare no conflicts of interest. This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare‐affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities. Acknowledgments The authors sincerely thank the patient and his family for providing consent to publish this information. Data Availability Statement Research data are not shared. References Associated Data Data Availability Statement Research data are not shared.